Last year saw the largest loss of revenue yet from major drugs due to patent expiries, but a continuation of 2011's higher level of drug approvals and new initiatives to address R&D challenges provide hope for the future.
Enjoying our latest content?
Log in or create an account to continue
- Access the most recent journalism from Nature's award-winning team
- Explore the latest features & opinion covering groundbreaking research
or
Rights and permissions
About this article
Cite this article
Tse, M., Kirkpatrick, P. 2012 in reflection. Nat Rev Drug Discov 12, 8–10 (2013). https://doi.org/10.1038/nrd3927
Published:
Issue date:
DOI: https://doi.org/10.1038/nrd3927
